Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 51407-0026
Overview of the Drug
NDC 51407-0026 corresponds to Sokograft, a recombinant human bone morphogenetic protein-2 (rhBMP-2) used in spinal fusion procedures. It is marketed by Medtronic, with approvals primarily in the United States. The product competes with other bone graft substitutes and is utilized in both clinical and surgical settings to enhance bone healing.
Market Size and Dynamics
Current Market Size
The global bone graft substitutes market is estimated at approximately $2.8 billion for 2022. The segment incorporating rhBMP-2 based products, including Sokograft, accounts for nearly 35-40% of this figure, translating to about $980 million.
Growth Drivers
- Rising prevalence of spinal degenerative diseases: The increase in aging population leads to higher demand for spinal surgeries.
- Advancements in surgical techniques: Minimally invasive procedures favor products with proven efficacy in fusion success.
- Regulatory approvals: Expanded indications for rhBMP-2 increase market penetration.
- Developments in product formulations: Improved delivery vectors and lower adverse effects extend market reach.
Competitive Landscape
Major competitors include Medtronic's Infuse Bone Graft, Medacta, and Stryker's alternatives. The market is driven by product differentiation, clinical efficacy, safety profiles, and pricing strategies.
Regulatory and Reimbursement Environment
- FDA approval since 2002 permits marketed use in spinal fusion; recent expansions include other surgical indications.
- Reimbursement policies favor rhBMP-2 products when used appropriately, with CMS partially reimbursing higher-cost devices due to improved outcomes.
- Concerns over adverse effects—such as inflammation and ectopic bone formation—have led to tighter usage guidelines, impacting sales volume.
Pricing Analysis
Current Price Point
- Retail costs per surgical procedure range from $1,200 to $4,500, depending on the formulation, dosage, and provider negotiations.
- Medtronic's Sokograft is positioned in the mid to upper range, typically around $3,000 to $3,500 per procedure.
Pricing Trends
- Prices have remained relatively stable over the past three years with minor fluctuations.
- Price reductions are observed in competitive bids, volume discounts, and payer negotiations.
- The cost of rhBMP-2 products often reflects indirect savings through quicker procedures and reduced reoperation rates.
Future Price Projections
| Year |
Estimated Price Range per Procedure |
Assumptions |
| 2023 |
$3,000 - $3,500 |
Stable market, controlled reimbursement policies |
| 2024 |
$2,800 - $3,400 |
Slight downward pressure due to increased competition |
| 2025 |
$2,700 - $3,200 |
Cost optimization and expanded use cases |
Anticipated downward pressure mainly results from:
- Increased competition from biosimilars and alternative graft materials.
- Market maturation leading to price stabilization.
- Policy shifts promoting cost containment.
Market Penetration and Usage Patterns
- Procedure volume: Approximately 250,000 to 300,000 spine fusion procedures annually in the U.S.
- Product utilization: Estimated at 70-80% of eligible surgeries, growing with expanded indications.
- Geographical variation: Higher adoption in North America (~80%), with slower growth in Asia-Pacific and Europe.
Key Risks and Opportunities
Risks
- Adverse safety reports could constrain sales.
- Regulatory restrictions or changes in reimbursement could reduce utilization.
- The emergence of cheaper, effective substitutes.
Opportunities
- Expanded indications in other orthopedic surgeries.
- Development of lower-cost formulations.
- Geographic expansion in emerging markets.
Key Takeaways
- The global bone graft substitutes market is around $2.8 billion, with rhBMP-2 products comprising roughly $980 million.
- The average price per procedure for Sokograft remains between $3,000 and $3,500.
- Market growth is driven by aging populations, surgical innovations, and clinical demand, but faces pricing stability challenges due to competition.
- Projections suggest slight price reductions in the coming years, especially as market saturation increases.
- Reimbursement policies and safety profiles significantly influence market dynamics and pricing strategies.
FAQs
1. How does Sokograft compare to other bone graft substitutes in price?
It is priced higher than synthetic grafts but remains competitive within rhBMP-2 segment options, especially considering clinical efficacy.
2. What factors could influence future prices for Sokograft?
Market competition, regulatory changes, safety concerns, and the development of biosimilars can affect pricing.
3. Is there potential for price increases in the near term?
Limited; market maturity and competitive pressures favor stable or decreasing prices unless new, superior indications are approved.
4. How does regional variation impact pricing?
Prices tend to be higher in North America due to higher healthcare expenditure and reimbursement levels. In emerging markets, prices are generally lower.
5. What is the outlook for innovative formulations of rhBMP-2?
Development of lower-cost or delivery-enhanced formulations could disrupt current pricing, potentially reducing costs while maintaining efficacy.
Citations:
[1] Market Study, "Bone Graft Substitutes Market," MarketsandMarkets, 2022.
[2] FDA, "RhBMP-2 Approvals and Indications," US Food and Drug Administration, 2022.
[3] Medtronic, "Sokograft Product Information," Official Website, 2023.
[4] Advisory Board, "Spinal Fusion Market Trends," 2022.
